baber/WOPTO huggingface dataset:
Patent JP-2001517177-A (JP)
Title: 鉄道車両用車輪の特性改善方法及び鉄道車両用車輪
IPC: B23P6/00
Filed: 1998-03-30
Abstract: (57)【要約】
本発明は、鉄道車両用車輪、及び鉄道車両用車輪（１）の特性改善方法に関する。この方法発明によると、車輪（１）の母材（２）の一部を除去し、その部分に特にレーザー照射による熱照射によって溶融物を形成し、溶融物に付加物を供給して、母材（２）と異なる特性を有する表面被覆層（１６、１７）を形成する。
Patent JP-H11509740-A (JP)
Title: 動物の収容施設を含む構造
IPC: A01J5/00
Filed: 1997-05-20
Abstract: (57)【要約】
本発明は乳牛等の動物の収容施設（１）を含む構造に関し、該施設（１）は、動物をマッサージするためのマッサージ部材（８）とブラッシングするためのブラッシング部材（３０）とを備えている。この構造はさらに長手方向案内手段（７、３１）を備え、これを介してマッサージ部材（８）および／またはブラッシング部材（３０）が動物の長手方向に移動できる。
Patent JP-2000515658-A (JP)
Title: 複雑なデジタル集積回路の設計方法並びに回路構造体
IPC: G06F17/50
Filed: 1998-04-08
Abstract: (57)【要約】
システムのデータ流に、算術的ないし論理的機能を備えた各１つの機能（ＡＬＵブロック）が割り当てられる。この機能はＲＡＭ制御を形成する。ＡＬＵブロックは、データ流の個々の処理課題に特殊化されている。ＲＡＭアドレスの瞬時状態並びにＲＡＭ出力データはＡＬＵブロックにフィードバックされる。動作時にＡＬＵブロックは交互にＲＡＭへの書き込みアクセスを形成する。各クロック毎にすべてのＡＬＵブロックの読み出しアクセスを行うことができ、これによりデータ流の出信号線路が制御される。レジスタは、ＡＬＵブロックがレジスタ段の間にあり、これによって公知のＣＡＤプログラムによる自動的な検査パターン発生を保証する。検査構造体でのコストが小さいことにより、基本回路の良好な検査性が最小の検査パターンセットを以て回路設計の早期段階で保証される。本発明の回路構造体はデジタルシグナルプロセッサとしても実施することができる。
Patent JP-2001527395-A (JP)
Title: 植物における長鎖多不飽和脂肪酸の合成のための方法および組成物
IPC: A23K1/16
Filed: 1998-04-10
Abstract: (57)【要約】
本発明は、植物、植物部位および植物細胞、例えば葉、根、果実および種子などにおいて、多不飽和長鎖脂肪酸を調製するための組成物および方法に関する。Δ5-デサチュラーゼ、Δ6-デサチュラーゼおよびΔ12-デサチュラーゼを含む脂肪酸デサチュラーゼをコードする核酸配列および構築物を使用して、１以上のデサチュラーゼをコードする１以上のトランスジーンを含み且つ発現するトランスジェニック植物、植物部位および細胞を作出する。植物系における異なる基質特異性を有するデサチュラーゼの発現により、植物、植物部位および組織の脂肪酸プロフィールの改変のための多不飽和長鎖脂肪酸（ドコサヘキサン酸、エイコサペンタン酸、α-リノレン酸、γ-リノレン酸、アラキドン酸などの）の大量生産が可能となる。脂肪酸プロフィールの操作により、商品価値のある新規植物油および製品の生産が可能となる。
Patent JP-2001523135-A (JP)
IPC: A61B17/12
Filed: 1998-04-24
Abstract: The present invention relates to a surgical retractor that immobilizes tissue at a surgical site. A preferred embodiment, of the retractor is used during minimally invasive direct coronary bypass procedures to arrest movement of the grafting site while the heart continues pumping. Tape or thread can be used to connect the artery to the retractor with a holder.
Patent JP-2000513497-A (JP)
Title: スペーサと局部的に薄い蛍光体層厚さとを有する蛍光ランプ
IPC: H01J61/30
Filed: 1999-04-09
Abstract: (57)【要約】
放電容器の壁２を支持するスペーサ６を有する蛍光ランプの説明がなされ、蛍光体層３はスペーサ６の周囲部位において厚さの減少する部位（８）を有する。
Patent MD-20060209-A (MD)
Title: Process for drying boiled sorize groats
Inventor: DODON Adelina
IPC: A23L5/30
Filed: 2006-08-14
Abstract: The invention refers to the food industry, namely to a process for drying boiled sorize groats.The process for drying boiled sorize groats consists in that concomitantly with drying by convection at the thermal agent temperature of 60...85°C it is applied heating of groats in electromagnetic field with the frequency of 2450 MHz and the magnetron power of 1,125 kW.
Patent MX-162588-A (MX)
Inventor: WIEZER HARMUT
IPC: C07D498/10
Filed: 1982-02-04
Abstract: Diazaspirodecanes of the general formulae   <IMAGE>    <IMAGE>  are reacted with epoxides or aldehydes to give alcohols and the latter are reacted with bifunctional compounds to form oligomers or polymers which can be used as light stabilizers for synthetic polymers. The alcohols can also be obtained if epoxy compounds which are substituted by the above diazaspirodecanes are converted into their formic acid esters and the latter are saponified.
Patent NZ-196260-A (NZ)
Title: Androstane carbothioates anti-inflammatory compositions
Inventor: PHILLIPS G H
IPC: B63H3/08
Filed: 1981-02-13
Abstract: Compounds of the formula <IMAGE> in which R<1> is a fluoro-, chloro- or bromomethyl group or a 2'-fluoroethyl group, R<2> is a group COR<6> in which R<6> is a C1-3-alkyl group, or OR<2> and R<3> together form a 16 alpha ,17 alpha -isopropylidenedioxy group; R<3> is a hydrogen atom, a methyl group (which can be present in either the  alpha  or the ss configuration) or a methylene group; R<4> is a hydrogen, chlorine or fluorine atom; R<5> is a hydrogen or fluorine atom, and the symbol ..... is a single or double bond. The compounds have good anti-inflammatory activity, in particular on topical application. The compounds of the formula I are prepared by esterification, halogenation, reduction, elimination of protective groups and reaction at a 9,11 double bond to form a 9 alpha -halo-11ss-hydroxy group.
Patent NZ-208990-A (NZ)
Title: Pyrrolidinone derivatives and pharmaceutical compositions
Inventor: WEBER K-H
IPC: C07D401/06
Filed: 1984-07-24
Abstract: Compounds of the formula   <IMAGE>   wherein R1 is hydrogen or alkyl of 1 to 4 carbon atoms; and R2 is pyridyl, phenyl or mono-, di- or tri-substituted phenyl, where the substituents are alkyl of 1 to 2 carbon atoms, alkoxy of 1 to 2 carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, nitro, benzyloxy or hydroxyl. The compounds are useful as nootropics.
Patent NZ-212507-A (NZ)
Title: Carbonating water by stirring action in chamber containing water and carbon dioxide gas
Inventor: SCOTT A
IPC: B01F3/04
Filed: 1985-06-21
Abstract: A carbonation method and apparatus is described in which carbonation is achieved by forcing carbon dioxide in gaseous form from an atmosphere thereof downwardly into a body of water to be carbonated. This may be achieved by a vaned rotor (3) rotatable about a horizontal axis or other means. The carbon dioxide atmosphere is preferably maintained at a pressure of about 100 psig (6.8 bars). The degree of carbonation may be varied by varying the time for which the carbonation operation is carried on. A flavour concentrate supply means, containing various flavours (46,48,50), is pressurized for the supply of the concentrate utilizing what would otherwise by waste carbon dioxide gas from the carbonation chamber after completion of the carbonation operation.
Patent NZ-216670-A (NZ)
Title: Benzodiazepin-6-one derivatives and pharmaceutical compositions
Inventor: EBERLEIN W
IPC: A61K31/55
Filed: 1986-06-26
Abstract: Compounds of general formula I are described,    <IMAGE>  (I) wherein X represents the group =CHR, =NR or an oxygen atom and A represents the groups -NR1R2, wherein R1 and R2 represent alkyl, cycloalkyl or phenylalkyl groups, n represents the number 0, 1 or 2, R3 represents a hydrogen atom, a hydroxy or alkyl group or a group -(CH2)n-N-R5R6 (R5 and R6 being lower alkyl groups) and R4 is an alkyl or phenylalkyl group; two processes for preparing these compounds and the salts thereof are also described. The compounds have favourable effects on heart rate and can be used as vagal pacemakers for treating bradycardia and bradyarrhythmia in human and veterinary medicine. Some of these compounds also have very good antithrombotic effects.
Patent NZ-218072-A (NZ)
Title: Phosphino-hydrocarbon-group viii metal complexes and pharmaceutical compositions
Inventor: TIMMER KLAAS
IPC: A61K31/285
Filed: 1986-10-28
Abstract: Novel bis[bis(diphenylphosphino)hydrocarbon] and bis[diphenylphosphino-diphenylarsino)hydrcarbon]-group VIII metal compounds of the formula 1 of the formula sheet, whereinD, = D<sub>2</sub> = phosphorus or D, = phosphorus and D<sub>2</sub> = arsenic;A = (CH<sub>2</sub>)<sub>2</sub> or cis-CH = CH;X, = X<sub>2</sub> (both if present) = halo or nitrato or X, + X = peroxo;Y (if present) = halide, nitrate, perchlorate, triflate or tetrahaloferrate (III);n = 0, 1 or 2;M = Fe(II), Fe(III), Co(II), Rh(I), Rh(III), Ir(I), Ir(III), Ni(II) or Pd(II),showing a tumor cell growth-inhibiting activity, novel pharmaceutical compositions containing said compounds and a method for treating tumor cells, sensitive to said compounds.
Patent NZ-220987-A (NZ)
Title: Carbamate and urea derivatives and pharmaceutical compositions thereof
Inventor: BEELEY N
IPC: C07C323/39
Filed: 1987-07-07
Abstract: A compound which is a carbamate or urea derivative of general formula (I)    <IMAGE>  (I)  wherein X is hydrogen, halogen or methylthio, Y is oxygen or   <IMAGE>  R is C1-C4 alkyl, R1 is hydrogen, one or two halogen atoms or trifluoromethyl groups, a methyl group, a methyl group, a cyano group, a nitro group, a methoxycarbonyl group, a methylenedioxy group linked to two adjacent carbon atoms of the benzene ring to which it is attached, or a fused benzo group forming an  alpha -naphthyl or  beta -naphthyl group with the benzene ring to which it is attached, R2 is a linear or branched C1-C8 alkyl or alkenyl group optionally substituted with halogen atoms or a methoxy group, a cyclopropylmethyl group, or a phenyl group optionally substituted with one or two halogen atoms or methyl groups, n is 1 or 2, and m is 2 or 3, or an addition salt thereof with a pharmacologically acceptable acid is pharmacologically active as a calcium antagonist.
Patent NZ-222069-A (NZ)
Title: Synergistic microbiocidal compositions
Inventor: YOSUKE ITO
IPC: A01N43/78
Filed: 1987-10-06
Abstract: A composition comprising a quaternary ammonium compound and 2-(thiocyanomethylthio)benzothiazole. The composition can be useful as a microbicide and preservative for preventing the deterioration of various types of industrial raw materials and products by inhibiting the growth of microorganisms.
Patent NZ-234861-A (NZ)
Title: Bradykinin antagonist peptides and pharmaceutical compositions
Inventor: HENKE STEPHAN
IPC: C07K1/06
Filed: 1990-08-10
Abstract: Peptides of the formula I A-B-C-E-F-K-(D)-Phe-G-M-F'-I (1> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, aryloyl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aromatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F or can be -NH-(CH2)2-8 or optionally a direct bond, I is -OH, -NH2 or -NHC2H5, and K is a radical -NH-(CH2)1-4-CO- or is a direct bond, act as bradykinin antagonists. Their therapeutic uses comprise all pathological states promoted, induced or assisted by bradykinin and bradykinin-related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.
Patent NZ-235076-A (NZ)
Title: Gastric retention device comprising a shape memory substance and a bioerodible substance, preparation and use as a drug delivery system
Inventor: TAKASHI SONOBE
IPC: A61K9/00
Filed: 1990-08-28
Abstract: A device for extended retention in the stomach, the device comprising a molding which comprises shape memory material (A) joined to or mixed with material erodible in vivo (B), said molding being of a size, shape and durability to remain in the stomach for a definite residence time. The device can be of a shape such as not to hinder passage of food in the stomach and is capable of being folded to an orally administrable form. It is used for drug delivery.
Patent NZ-235465-A (NZ)
Title: Process for preparing purine derivatives; intermediates
Inventor: GEEN GRAHAM RICHARD
IPC: C07D473/24
Filed: 1990-09-26
Abstract: A process for the preparation of a compound of formula (A): <CHEM> wherein X is hydrogen, hydroxy, chloro, C1-6 alkoxy or phenyl C1-6 alkoxy and Ra and Rb are hydrogen, including acyl and phosphate derivatives thereof; which process comprises:  i) the preparation of a compound of formula (I): <CHEM> wherein R1 is C1-6 alkyl, or phenyl C1-6 alkyl in which the phenyl group is optionally substituted; R2 is hydrogen, hydroxy, chlorine, C1-6 alkoxy, phenyl C1-6 alkoxy or amino; and R3 is halogen, C1-6 alkylthio, C1-6 alkylsulphonyl, azido, an amino group or a protected amino group, which process comprises the reaction of a compound of formula (II): <CHEM>  with a compound of formula (VII): <CHEM> wherein Q is a leaving group, J is hydrogen or halo and R1 is as hereinbefore defined; to give a compound of formula (VIII): <CHEM> followed by reduction of the compound of formula (VIII) to give a compound of formula (I) as hereinbefore defined; and, as necessary or desired, interconverting variables R1, R2 and R3 to further values of R1, R2 and R3; (ii) the conversion of the resulting compound of formula (I) to a compound of formula (A) by converting variable R3, when other than amino, to amino, reducing the ester groups CO2R1 to CH2OH and optionally forming acyl or phosphate derivatives thereof, and as necessary or desired converting variable R2 in the compound of formula (I) to variable X in the compound of formula (A).
Patent NZ-243681-A (NZ)
Title: Optionally heterocyclically substituted 1,3,5-triazine derivatives and medicaments
Inventor: VAN KEULEN BEREND JAN
IPC: A61P25/24
Filed: 1992-07-23
Abstract: New cyclopropylamino-1,3,5-triazines and their salts, processes for their preparation and therapeutic compositions. These compounds correspond to the formula <IMAGE>  in which     R1 = alkyl, cycloalkyl or alkylcycloalkyl, R2 = bis(2-hydroxyethyl)amino, 3-hydroxy-1-azetidinyl, 3-methoxy-1-azetidinyl, 3-oxo-1-azetidinyl, morpholino, 4-hydroxypiperidino, thiomorpholino, thiomorpholino S-oxide, thiomorpholino S,S-dioxide, 3-thiazolidinyl, 3-thiazolidinyl S-oxide, 3-thiazolidinyl S,S-dioxide or 8-oxa-3-azabicyclo[3.2.1]oct-3-yl.   These compounds are useful in the treatment of disorders associated with Alzheimer's disease, Alzheimer-type senile dementias and all evolutive cognitive pathologies and in the treatment of depression, anxiety, mood disorders, inflammatory phenomena and asthma.
Patent NZ-277549-A (NZ)
Title: Keyboard apparatus; arrangement of keys
Inventor: KATO YOSHIYA
IPC: G06F3/00
Filed: 1994-12-26
Abstract: PCT No. PCT/JP94/02216 Sec. 371 Date Jan. 4, 1996 Sec. 102(e) Date Jan. 4, 1996 PCT Filed Dec. 26, 1994 PCT Pub. No. WO95/18405 PCT Pub. Date Jul. 6, 1995A keyboard-type input apparatus has a main key area consisting of at least fifteen keys arranged in a three-line and five-column state to include a basic side either on right or left side of the column, of which two-column belongs to the basic side being provided as a vowel sound area to input vowel sounds and other columns composed of three-column being provided as a consonant sound area to input consonant sounds.
Patent NZ-277662-A (NZ)
Title: Poly-beta-1,4-n-acetylglucosamine comprising 4000 to 15000 n-acetylglucosamines free of protein and other contaminants; use in preventing post-surgical adhesions and in drug delivery systems
Inventor: VOURNAKIS JOHN N
IPC: A61L31/04
Filed: 1994-12-01
Abstract: The present invention relates, first, to a purified, easily produced poly- beta -1->4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a  beta -1->4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. <??>Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
Patent NZ-292782-A (NZ)
Title: Ant-inflammatory benzofuran and benzothiophene derivatives and medicaments thereof
Inventor: SCHERZ MICHAEL WIARD
IPC: A61P29/00
Filed: 1995-09-06
Abstract: A compound having the structure:   <IMAGE>   wherein (a) W is -C(X')-NRR' or -NR-C(X')R'; (b) X and X' are independently O or S; (c) each Y is independently hydrogen or straight, branched or cyclic alkanyl having from 1 to about 3 carbon atoms, or the two Y's are bonded to form an alkanyl ring having from 3 to about 7 carbon atoms; (d) Z is unsubstituted branched or cyclic alkyl, or unsubstituted or alkanyl-substituted phenyl or benzyl, Z having from 3 to about 10 atoms other than hydrogen; (e) R and R' are each independently selected from hydrogen, hydroxy straight, branched or substituted alkyl having from 1 to about 6 carbon atoms, and cyclic alkyl having from 3 to about 7 carbon atoms; unsubstituted or substituted aryl, heteroaryl or heterocyclic groups; or R and R' are bonded together to form a ring having from from 3 to about 8 atoms wherein about 1 to about 4 atoms may be heteroatoms; pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.
Patent NZ-299115-A (NZ)
Title: Ostomy, incontinence or wound care coupling element with undercut formation having radially extending and circumferentially spaced ledges which have suitable taper angle for effective coupling
Inventor: KILGOUR RICHARD DEREK
IPC: A61M27/00
Filed: 1993-05-10
Abstract: A method of injection moulding an undercut formation (26) on a circular body (20) wherein said formation is moulded in a series of arcuate sections (28) alternating with spaces (29), and wherein the moulding core (24) which produces the formation is extracted by firstly relatively rotating said body (20) and said core (24) so that the body is expanded radially and then ejecting the body off the core. The method is applicable to the manufacture of novel closure members and coupling elements. <IMAGE>
Patent NZ-306105-A (NZ)
Title: A method for processing gold-bearing sulfide ores involving preparation of a sulfide concentrate
Inventor: SIMMONS GARY L
IPC: C07C1/04
Filed: 1996-03-22
Abstract: Provided is a method for processing a gold-bearing sulfide ore (102) which involves maintaining the ore in a substantially oxygen-free environment, preferably beginning with comminution of the ore and ending when a desired final concentrate (116), enriched in sulfide minerals, is obtained by flotation. In one embodiment, nitrogen gas (110) is used to substantially prevent contact between the ore and air during comminution (104) of the ore and during flotation (112) operations.  It is believed that oxygen gas present in air detrimentally affects the recovery of sulfide minerals in a flotation concentrate through surface oxidation of sulfide mineral particles. The use of a gas such as nitrogen can significantly reduce the potential for such surface oxidation.  Additionally, gases separated from an oxygen plant may be beneficially used, with an oxygen gas stream being used, for example, for pressure oxidation of sulfide mineral materials, and with a nitrogen gas stream being used in comminution and/or flotation operations, resulting in advantageous use of a nitrogen gas by-product stream which has previously been vented to the atmosphere as waste.
Patent NZ-325735-A (NZ)
Title: 4-substituted piperidine analogs, compositions containing the same and the method of using them as active antagonists of NMDA receptors
Inventor: BIGGE CHRISTOPHER F
IPC: A61K31/505
Filed: 1996-12-20
Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof is claimed wherein Ar1 and Ar2 are independently optionally substituted aryl or heteroaryl; z is  a single or double bond; X is -(CHR2)m-, O, S or NR3 provided that when z is a double bond then X is not O, S or NR3; R1 is H or OH; n is 0 to 2; R4 is H or OH when z is a single bond provided that: (i) when n is 0 then z is a double bond and R4 is not present; (ii) when n is 1 or 2 and Q is -CºC- and z is a double bond or R4 is OH then Ar1 is an aryl substituted by halogen and (iii) when R4 is OH then R2 is not OH or alkoxy. A pharmaceutical composition containing a compound of formula useful in treating disorders responsive to the selective blockade of N-methyl-D-aspartate receptor subtypes is claimed. Also claimed is a process to prepare the compounds of formula I.
Patent NZ-329258-A (NZ)
Title: Cyclic imide derivatives, pharmaceutical compositions thereof
Inventor: MULLER GEORGE W
IPC: A61K31/415
Filed: 1994-07-01
Abstract: A process of preparing thalidomide in which N-phthaloylglutamine or N-phthaloylisoglutamine is cyclized with N,N'-carbonyldiimidazole, characterised in that the process comprises heating said N-phthaloylglutamine or N-phthaloylisoglutamine and N,N'-carbonyldiimidazole in refluxing anhydrous tetrahydrofuran.
Patent NZ-333231-A (NZ)
Title: Biochemical analysis of antioxidant function using cumene hyperoxide (CuOOH)
Inventor: CRAWFORD J FRED
IPC: C12N5/02
Filed: 1997-06-18
Abstract: he application provides a cell culture medium useful for a biochemical analysis of antioxidant function in human lymphocytes, the medium comprising: a buffered, serum-free solution containing the following ingredients:  a carbohydrate selected from the group consisting of glucose and a compound biologically capable of producing glucose in the cells;  a biologically usable form of pantothenic acid;  choline or a biological usable form of a substance capable of producing choline in the cells; and  inorganic ions comprising chloride, phosphate, calcium, magnesium, potassium, sodium; and iron in a biologically utilizable form,  cumene hydroperoxide, deionized water, and a mitogen in an amount effective to stimulate the lymphocytes being assayed; said buffered, serum-free solution having a pH from about 6.8 to 7.6, said cell culture medium characterized by being effective to determine nutritional deficiencies, inadequacies, and imbalances and to biochemically analyze antioxidant function of the lymphocytes. Also provided is a method of biochemically analyzing cellular antioxidant function in an individual comprising the steps of: inoculating the cell culture medium of the present invention with lymphocytes from said individual; incubating the inoculated cell culture medium; and comparing the response of the lymphocytes with an average response of lymphocytes from a control group of individuals.
Patent NZ-335133-A (NZ)
Title: Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof for treating cancer
Inventor: DESAI NEIL P
IPC: A61K47/42
Filed: 1997-09-24
Abstract: A method for the preparation of a substantially water insoluble pharmacologically active agent for in vivo delivery, said method comprising subjecting a mixture comprising an organic phase containing the pharmacologically active agent dispersed therein, and an aqueous medium containing biocompatible polymer, (the mixture containing substantially no surfactants), to high shear conditions in a high pressure homogenizer at a pressure in the range of about 3,000 up to 30,000 psi. Also disclosed is a drug delivery system that comprises particles of a solid or liquid, substantially water insoluble pharmacologically active agent, coated with protein, wherein the protein coating has free protein associated therewith.  A portion of the pharmacologically active agent is contained within the protein coating and a portion of the pharmacologically active agent is associated with the free protein.  The average diameter of the particles is no greater than about 1 micron.